Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

January 13, 2011 Approval Letter - DECAVAC

Our STN:   BL 103921-5149

Sanofi Pasteur Inc.
Attention:  Joseph H. Quinn
Discovery Drive, Swiftwater, PA 18370

Dear Mr. Quinn:

We have approved your request to supplement your biologics license application for DECAVAC® (Tetanus and Diphtheria Toxoids Adsorbed), to revise labeling to address latex hypersensitivity in the Precautions section of the package insert, and to correct the information regarding the tip caps of the prefilled syringes to state that they may contain natural rubber latex.  These labeling changes were made at CBER’s request since we have determined that information from the manufacturer of the tip caps is inadequate to support the claim that the tip caps do not contain latex.

Please submit all final printed labeling at the time of use and include implementation information on Form FDA 356h.  Please provide content of labeling in Structured Product Labeling format.  Please provide carton and container labeling in Structured Product Labeling format, as well as three original paper copies. 

We will include the information contained in the above referenced supplement in your Biologics License Application file.

Sincerely yours,


Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling

Resources for You

Page Last Updated: 01/21/2011
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.